Skip to main content
SpringerLink
Log in

Guidelines for Therapeutic Management of Parkinson’s Disease in China

  • Reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 33 Accesses

Abstract

Parkinson’s disease (PD) is the most common age-related neurodegenerative movement disorder, affecting around 1.7% of the population over 65 years old in China. The pathological feature of PD is the accumulation of α-synuclein-containing intraneuronal inclusions and progressive loss of dopaminergic neurons in midbrains. PD is clinically characterized by both motor and non-motor symptoms. In the past 20 years, Chinese researchers and clinicians have made significant progress in understanding the pathogenesis of PD, discovering biomarkers for early diagnosis, and developing novel therapeutic strategies to combat this disease. Until now, the Chinese Society of Parkinson’s Disease and Movement Disorders have published four editions of the Chinese Parkinson’s Disease Treatment Guidelines in 2006, 2009, 2014, and 2020. In this chapter, we will describe the main contents of these guidelines and summarize recent progress of PD treatment in China.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 949.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,399.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Aarsland D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217–31.

    PubMed  PubMed Central  Google Scholar 

  • Antonini A, et al. Medical and surgical management of advanced Parkinson’s disease. Mov Disord. 2018;33(6):900–8.

    PubMed  Google Scholar 

  • Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–60.

    PubMed  Google Scholar 

  • Barone P, et al. Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson’s disease. Neurology. 2004;63(8 Suppl 3):S35–8.

    PubMed  Google Scholar 

  • Bloem BR, de Vries NM, Ebersbach G. Nonpharmacological treatments for patients with Parkinson’s disease. Mov Disord. 2015;30(11):1504–20.

    PubMed  Google Scholar 

  • Bressman S, Saunders-Pullman R. When to start Levodopa therapy for Parkinson’s disease. N Engl J Med. 2019;380(4):389–90.

    PubMed  Google Scholar 

  • Broen MP, et al. Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2016;31(8):1125–33.

    PubMed  Google Scholar 

  • Cabreira V, Soares-da-Silva P, Massano J. Contemporary options for the management of motor complications in Parkinson’s disease: updated clinical review. Drugs. 2019;79(6):593–608.

    CAS  PubMed  Google Scholar 

  • Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–74.

    CAS  PubMed  Google Scholar 

  • Chaudhuri KR, et al. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–45.

    PubMed  Google Scholar 

  • Chen W, et al. Non-motor symptoms of Parkinson’s disease in China: a review of the literature. Parkinsonism Relat Disord. 2012;18(5):446–52.

    PubMed  Google Scholar 

  • Chen W, et al. Prevalence of wearing-off and dyskinesia among the patients with Parkinson’s disease on levodopa therapy: a multi-center registry survey in mainland China. Transl Neurodegener. 2014;3(1):26.

    PubMed  PubMed Central  Google Scholar 

  • Chen H, et al. Traditional Chinese Medicine symptom pattern analysis for Parkinson’s disease. J Tradit Chin Med. 2017;37(5):688–94.

    PubMed  Google Scholar 

  • Chinese Expert Group on Deep Brain Stimulation Therapy for Parkinson’s Disease. Consensus of Chinese experts on deep brain stimulation therapy for Parkinson’s Disease. Chin J Neurol. 2012;45(7):541–3.

    Google Scholar 

  • Chinese Society of Functional Neurosurgery, Chinese Society of Parkinson’s Disease and Movement Disorders, Parkinson’s Disease and Movement Disorder Section of Neurology Branch of Chinese Medical Doctor Association, et al. Expert consensus on deep brain stimulation therapy for Parkinson’s disease in China (second edition). Chin J Neurosurg. 2020;36(4):325–37.

    Google Scholar 

  • Chinese Society of Movement Disorders and Parkinson’s Disease. Guidelines for treatment of Parkinson’s disease. Chin J Neurol. 2006;39(6):409–12.

    Google Scholar 

  • Chinese Society of Parkinson’s Disease and Movement Disorders. Chinese guidelines for the treatment of Parkinson’s disease (2nd Edition). Chin J Neurol. 2009;42(5):352–5.

    Google Scholar 

  • Chinese Society of Parkinson’s Disease and Movement Disorders. Chinese guidelines for the treatment of Parkinson’s disease (3rd Edition). Chin J Neurol. 2014;47

    Google Scholar 

  • Chinese Society of Parkinson’s Disease and Movement Disorders. Chinese guidelines for the treatment of Parkinson’s disease (4th Edition). Chin J Neurol. 2020;53(12):973–86.

    Google Scholar 

  • Cilia R, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731–42.

    PubMed  PubMed Central  Google Scholar 

  • Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–83.

    PubMed  Google Scholar 

  • Debu B, et al. Managing gait, balance, and posture in Parkinson’s disease. Curr Neurol Neurosci Rep. 2018;18(5):23.

    PubMed  Google Scholar 

  • Ekker MS, et al. Neurorehabilitation for Parkinson’s disease: future perspectives for behavioural adaptation. Parkinsonism Relat Disord. 2016;22(Suppl 1):S73–7.

    PubMed  Google Scholar 

  • Fabbri M, Rosa MM, Ferreira JJ. Adjunctive therapies in Parkinson’s disease: how to choose the best treatment strategy approach. Drugs Aging. 2018;35(12):1041–54.

    PubMed  Google Scholar 

  • Ferreira JJ, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5–15.

    CAS  PubMed  Google Scholar 

  • Fox SH, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248–66.

    CAS  PubMed  Google Scholar 

  • Goodarzi Z, et al. Detecting depression in Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;87(4):426–37.

    PubMed  PubMed Central  Google Scholar 

  • Holloway RG, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044–53.

    PubMed  Google Scholar 

  • Jost WH, Buhmann C. The challenge of pain in the pharmacological management of Parkinson’s disease. Expert Opin Pharmacother. 2019;20(15):1847–54.

    PubMed  Google Scholar 

  • Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912.

    CAS  PubMed  Google Scholar 

  • Koychev I, Okai D. Cognitive-behavioural therapy for non-motor symptoms of Parkinson’s disease: a clinical review. Evid Based Ment Health. 2017;20(1):15–20.

    PubMed  Google Scholar 

  • Li G, et al. Parkinson’s disease in China: a forty-year growing track of bedside work. Transl Neurodegener. 2019;8:22.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Liu CF, et al. Management recommendations on sleep disturbance of patients with Parkinson’s disease. Chin Med J (Engl). 2018;131(24):2976–85.

    CAS  PubMed  Google Scholar 

  • Liu G, et al. Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson’s disease: a pilot study. Neurol Sci. 2020;41(1):111–8.

    PubMed  Google Scholar 

  • Lizarraga KJ, et al. Hallucinations, delusions and impulse control disorders in Parkinson disease. Clin Geriatr Med. 2020;36(1):105–18.

    PubMed  Google Scholar 

  • Morgenthaler T, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine Report. Sleep. 2006;29(11):1415–9.

    PubMed  Google Scholar 

  • National Institute for Health and Care Excellence: Clinical Guidelines. Parkinson’s disease in adults: diagnosis and management. 2017.

    Google Scholar 

  • Okun MS. Management of Parkinson disease in 2017: personalized approaches for patient-specific needs. JAMA. 2017;318(9):791–2.

    PubMed  Google Scholar 

  • Olanow CW, Stocchi F. COMT inhibitors in Parkinson’s disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology. 2004;62(1 Suppl 1):S72–81.

    CAS  PubMed  Google Scholar 

  • Olanow CW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361(13):1268–78.

    CAS  PubMed  Google Scholar 

  • Pahwa R, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983–95.

    CAS  PubMed  Google Scholar 

  • Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328(3):176–83.

    Google Scholar 

  • Poewe W, et al. Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging. 2010;5:229–38.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Poewe W, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.

    PubMed  Google Scholar 

  • Radder DLM, et al. Multidisciplinary care for people with Parkinson’s disease: the new kids on the block! Expert Rev Neurother. 2019;19(2):145–57.

    CAS  PubMed  Google Scholar 

  • Rascol O, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484–91.

    CAS  PubMed  Google Scholar 

  • Rukavina K, et al. Pain in Parkinson’s disease: new concepts in pathogenesis and treatment. Curr Opin Neurol. 2019;32(4):579–88.

    CAS  PubMed  Google Scholar 

  • Santos-Garcia D, de la Fuente-Fernandez R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson’s disease. J Neurol Sci. 2013;332(1-2):136–40.

    PubMed  Google Scholar 

  • Schneider RB, Biglan KM. The promise of telemedicine for chronic neurological disorders: the example of Parkinson’s disease. Lancet Neurol. 2017;16(7):541–51.

    PubMed  Google Scholar 

  • Schneider RB, Iourinets J, Richard IH. Parkinson’s disease psychosis: presentation, diagnosis and management. Neurodegener Dis Manag. 2017;7(6):365–76.

    PubMed  Google Scholar 

  • Seppi K, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180–98.

    PubMed  PubMed Central  Google Scholar 

  • Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology. 2004;62(1 Suppl 1):S56–63.

    CAS  PubMed  Google Scholar 

  • Stocchi F, et al. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord. 2011;26(7):1259–65.

    PubMed  Google Scholar 

  • Torti M, et al. Are all dopamine agonists essentially the same? Drugs. 2019;79(7):693–703.

    CAS  PubMed  Google Scholar 

  • Vacca VM Jr. Parkinson disease: enhance nursing knowledge. Nursing. 2019;49(11):24–32.

    PubMed  Google Scholar 

  • Vargas AP, Cardoso FEC. Impulse control and related disorders in Parkinson’s disease. Arq Neuropsiquiatr. 2018;76(6):399–410.

    PubMed  Google Scholar 

  • Warren Olanow C, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–71.

    CAS  PubMed  Google Scholar 

  • Weintraub D, Mamikonyan E. Impulse control disorders in Parkinson’s disease. Am J Psychiatry. 2019;176(1):5–11.

    PubMed  Google Scholar 

  • Weintraub D, et al. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30(2):121–7.

    CAS  PubMed  Google Scholar 

  • Whone AL, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54(1):93–101.

    CAS  PubMed  Google Scholar 

  • Winkelmann J, et al. Treatment of restless legs syndrome: evidence-based review and implications for clinical practice (Revised 2017) (section sign). Mov Disord. 2018;33(7):1077–91.

    PubMed  Google Scholar 

  • Zhan ZX, et al. A multiple center, randomized, double-blind, placebocontrolled clinical trial of entacapone in Parkinson’s disease patients with motor fluctuation. Chin J Neurol. 2003;36(6):406–10.

    Google Scholar 

  • Zhan A, et al. Using smartphones and machine learning to quantify Parkinson disease severity: the mobile Parkinson disease score. JAMA Neurol. 2018;75(7):876–80.

    PubMed  PubMed Central  Google Scholar 

  • Zhang ZX, et al. Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet. 2005;365(9459):595–7.

    PubMed  Google Scholar 

Download references

Acknowledgments

Thanks to all the members of Chinese Society of Parkinson’s Disease and Movement Disorders, and members of Parkinson’s Disease and Movement Disorder Section of Neurologist Branch of Chinese Medical Doctor Association.

Author information

Author notes

  1. Lin Lu and Yuting Yang contributed equally with all other contributors.

Authors and Affiliations

  1. Department of Neurology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    Lin Lu, Yangfu Luo & Pingyi Xu

  2. Department of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Shengdi Chen

  3. Liaoning Provincial Key Laboratory for Research on the Pathogenic Mechanisms of Neurological Diseases, The First Affiliated Hospital, Dalian Medical University, Dalian, China

    Yuting Yang & Weidong Le

  4. Liaoning Provincial Center for Clinical Research on Neurological Diseases, The First Affiliated Hospital, Dalian Medical University, Dalian, China

    Yuting Yang & Weidong Le

Authors
  1. Lin Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shengdi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuting Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yangfu Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pingyi Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weidong Le
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Pingyi Xu or Weidong Le .

Editor information

Editors and Affiliations

  1. Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, Wuerzburg, Germany

    Peter Riederer

  2. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

  3. Centre for Research Promotion and Support, Fujita Health University, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Germany

    Christian Riederer

Section Editor information

  1. Center for Research Promotion and Support, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  2. Department of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Akira Nakashima

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Lu, L., Chen, S., Yang, Y., Luo, Y., Xu, P., Le, W. (2022). Guidelines for Therapeutic Management of Parkinson’s Disease in China. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_358

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62059-2_358

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62058-5

  • Online ISBN: 978-3-030-62059-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation